Targanta Therapeutics Corporation (NASDAQ: TARG)

Targanta Therapeutics Corporation (NASDAQ: TARG), a biopharmaceutical company, is dedicated to developing and commercializing innovative antibiotics that treat serious infections in the hospital and other institutional settings. The company’s lead antibiotic, oritavancin, is designed to treat serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Additionally, Targanta is developing multiple antibacterial agents, including an oral version of oritavancin targeting Clostridium difficile-related conditions. For further information, visit the Company’s web site at www.targanta.com.